Heidy King-Jones Sells 27,999 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

Posted by Geri Gentry on Sep 5th, 2026

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) insider Heidy King-Jones sold 27,999 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $87.31, for a total value of $2,444,592.69. Following the transaction, the insider directly owned 2,845 shares in the company, valued at approximately $248,396.95. This represents a 90.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Heidy King-Jones also recently made the following trade(s):

On Wednesday, September 2nd, Heidy King-Jones sold 400 shares of Spyre Therapeutics stock. The shares were sold at an average price of $90.00, for a total value of $36,000.00.

Spyre Therapeutics Price Performance

Spyre Therapeutics stock opened at $88.98 on Friday. The business has a 50 day simple moving average of $98.05 and a 200-day simple moving average of $74.63. Spyre Therapeutics, Inc. has a 12 month low of $14.51 and a 12 month high of $110.18. The stock has a market capitalization of $7.82 billion, a PE ratio of -45.63 and a beta of 2.99.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.40. As a group, equities research analysts anticipate that Spyre Therapeutics, Inc. will post -2.62 EPS for the current year.

Hedge Funds Weigh In On Spyre Therapeutics

A number of large investors have recently made changes to their positions in SYRE. Summit Securities Group LLC purchased a new stake in Spyre Therapeutics during the first quarter worth about $28,000. GAMMA Investing LLC grew its position in Spyre Therapeutics by 26.8% during the second quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $59,000 after buying an additional 140 shares during the period. KBC Group NV purchased a new position in Spyre Therapeutics in the first quarter valued at about $69,000. Russell Investments Group Ltd. increased its holdings in Spyre Therapeutics by 2,881.7% in the third quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after buying an additional 4,092 shares in the last quarter. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Spyre Therapeutics during the 4th quarter valued at approximately $74,000. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Key Headlines Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

Positive Sentiment: Management will participate in the Citi BioPharma Back to School Conference on September 9, the Wells Fargo Healthcare Conference on September 10, and the Stifel Immunology and Inflammation Forum on September 23. These events could provide updates on Spyre’s clinical programs, development strategy, and potential catalysts. Spyre Therapeutics to Participate in Upcoming September Investor Conferences
Positive Sentiment: Spyre’s independent compensation committee approved stock options covering 2,106 shares and 745 restricted stock units for a new non-executive employee. The awards were intended to secure the employee’s acceptance and may support the company’s ability to recruit talent, although the equity issuance has a modest dilution effect. Spyre Therapeutics Announces Grants of Inducement Awards
Neutral Sentiment: Spyre’s latest quarterly loss of $0.36 per share was better than the expected $0.76 loss. However, the company remains unprofitable, with analysts forecasting a full-year loss of approximately $2.62 per share. The earnings beat alone has not provided a lasting catalyst.
Negative Sentiment: Several insiders reported sales totaling roughly 69,000 shares. CEO Cameron Turtle sold 15,000 shares, CFO Scott Burrows sold 25,732 shares, and Heidy King-Jones sold 28,399 shares. The transactions were made under pre-arranged Rule 10b5-1 plans; Burrows said his sales covered tax withholding obligations. Even so, the volume of selling—particularly King-Jones’s substantial reduction in ownership—could weigh on investor sentiment. Spyre Therapeutics Insider Trading
Negative Sentiment: A Zacks report noted that SYRE had declined 16.6% since its latest earnings release, suggesting investors remain focused on the need for clinical progress and additional company-specific catalysts. Spyre Therapeutics Down 16.6% Since Last Earnings Report

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. BTIG Research cut their price target on shares of Spyre Therapeutics from $132.00 to $121.00 and set a “buy” rating for the company in a report on Wednesday, August 26th. Wolfe Research lowered Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Tuesday, July 28th. Wall Street Zen cut Spyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Mizuho increased their target price on Spyre Therapeutics from $84.00 to $120.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Spyre Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $109.69.

Check Out Our Latest Analysis on SYRE

About Spyre Therapeutics

(Get Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.